Genetic assessment using whole-exome sequencing for a young hypertriglyceridemic patient with repeated acute pancreatitis.

Hypertriglyceridemia is caused not only by environmental factors but also by genetic factors. Severe hypertriglyceridemia is prone to complications of acute pancreatitis. Here, we report a whole-exome sequencing (WES) analysis for a young hypertriglyceridemic patient with recurrent acute pancreatitis and the patient's mother. A 28-year-old hypertriglyceridemic female was admitted to our hospital. At 23 years old, a health checkup clarified her hypertriglyceridemia. At the age of 26 and 27, she had repeated acute pancreatitis with severe hypertriglyceridemia (serum triglyceride level were 3,888 mg/dL and 12,080 mg/dL, respectively). The patient's BMI was 29.0 kg/m2, and blood samples under fibrate medication showed triglyceride 451 mg/dL and HbA1c 7.2%. Type V dyslipidemia became more apparent at postprandial state. The WES analysis showed that the patients had two heterozygous variants in Apolipoprotein A5 (APOA5) gene (p.G185C and p.V153M), a heterozygous variant in Apolipoprotein E (APOE) gene (p.R176C), three heterozygous variants in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene (p.T1220I, p.R1453W and p.V470M). On the other hand, her mother, who had moderate hypertriglyceridemia without acute pancreatitis, had a heterozygous variant in APOA5 gene (p.G185C) and two heterozygous variants in CFTR gene (p.T1220I and p.V470M). These results suggest that the more severe pathology of the patient than her mother might be due to the possible compound heterozygous APOA5 variants, the heterozygous APOE variant, and the possible compound heterozygous CFTR variants. In this case, WES analyses were useful to evaluate not only the causative genes of hypertriglyceridemia (APOA5 and APOE) but also the genes involved in the development of acute pancreatitis (CFTR) simultaneously.

[1]  D. Cooper,et al.  SPINK1, PRSS1, CTRC, and CFTR Genotypes Influence Disease Onset and Clinical Outcomes in Chronic Pancreatitis , 2018, Clinical and Translational Gastroenterology.

[2]  Yan Guo,et al.  Targeted Gene Next‐Generation Sequencing in Chinese Children with Chronic Pancreatitis and Acute Recurrent Pancreatitis , 2017, The Journal of pediatrics.

[3]  A. Masamune,et al.  Targeted Next-Generation Sequencing Effectively Analyzed the Cystic Fibrosis Transmembrane Conductance Regulator Gene in Pancreatitis , 2015, Digestive Diseases and Sciences.

[4]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[5]  N. Ewald,et al.  Current knowledge of hypertriglyceridemic pancreatitis. , 2014, European journal of internal medicine.

[6]  K. Wenner,et al.  Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant. , 2014, Atherosclerosis.

[7]  D. Yadav,et al.  Issues in hypertriglyceridemic pancreatitis: an update. , 2014, Journal of clinical gastroenterology.

[8]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[9]  A. Masamune Genetics of pancreatitis: the 2014 update. , 2014, The Tohoku journal of experimental medicine.

[10]  M. Stumvoll,et al.  CFTR, SPINK1, CTRC and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? , 2012, Gut.

[11]  J. Rotter,et al.  The lipoprotein lipase (LPL) S447X gain of function variant involves increased mRNA translation. , 2012, Atherosclerosis.

[12]  Joseph L Goldstein,et al.  LXR-SREBP-1c-Phospholipid Transfer Protein Axis Controls Very Low Density Lipoprotein (VLDL) Particle Size* , 2009, The Journal of Biological Chemistry.

[13]  P. Talmud,et al.  ANGPTL4 E40K and T266M: Effects on Plasma Triglyceride and HDL Levels, Postprandial Responses, and CHD Risk , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[14]  J. Graaf,et al.  A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[15]  P. Talmud Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review. , 2007, Atherosclerosis.

[16]  T. Murano,et al.  The recovery of dysfunctional lipoprotein lipase (Asp204-Glu) activity by modification of substrate. , 2005, Atherosclerosis.

[17]  Min Goo Lee,et al.  A haplotype-based molecular analysis of CFTR mutations associated with respiratory and pancreatic diseases. , 2003, Human molecular genetics.

[18]  M. Knowles,et al.  Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. , 2001, Gastroenterology.

[19]  S. Freedman,et al.  Pancreatic acinar cell dysfunction in CFTR(-/-) mice is associated with impairments in luminal pH and endocytosis. , 2001, Gastroenterology.

[20]  K. Shirai,et al.  Lipoprotein lipase mass and activity in severe hypertriglyceridemia. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[21]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[22]  E. Stroes,et al.  Diagnostic algorithm for familial chylomicronemia syndrome. , 2017, Atherosclerosis Supplements.

[23]  R. Havel Pathogenesis, differentiation and management of hypertriglyceridemia. , 1969, Advances in internal medicine.